35,002
Participants
Start Date
January 1, 1977
Primary Completion Date
December 31, 2014
Study Completion Date
July 30, 2016
Endocrine therapy
Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Radiotherapy
Radiotherapy versus no radiotherapy.
Herceptin
Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
Chemotherapy
Chemotherapy versus no chemotherapy.
Type of breast cancer surgery
Type of surgery (partial mastectomy, mastectomy, other).
Age at diagnosis
Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
Screen detected tumor
Screening detected tumor (yes, no).
Menopausal status at diagnosis
Menopausal status (premenopausal, postmenopausal).
Tumor size
Tumor size (≤5 mm, 6-≤10 mm).
Estrogen receptor (ER) status
ER-status (positive, negative).
Tumor grade
Tumor grade (1, 2, 3).
HER2-status
HER2-status (positive, negative).
Intrinsic subgroups of breast cancer
Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
Nodal status
N-status (N0, N1).
Karolinska Instiutet, Solna
The Swedish Society of Medicine
OTHER
The Swedish Breast Cancer Association (BRO)
UNKNOWN
Swedish Breast Cancer Group
OTHER
Karolinska Institutet
OTHER